<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Surgery</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/95D46800-A4DF-40AC-8FD3-7EAF5194B22C"><gtr:id>95D46800-A4DF-40AC-8FD3-7EAF5194B22C</gtr:id><gtr:firstName>Norman</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Maitland</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E21F9419-E970-4374-AAA6-C0C97401C46E"><gtr:id>E21F9419-E970-4374-AAA6-C0C97401C46E</gtr:id><gtr:firstName>Jenny</gtr:firstName><gtr:surname>Donovan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/919C856C-451C-40F1-A5E3-90742AEA6997"><gtr:id>919C856C-451C-40F1-A5E3-90742AEA6997</gtr:id><gtr:firstName>F</gtr:firstName><gtr:surname>Hamdy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/63E0AEE1-6D8D-4425-A06A-F4A943FFAF21"><gtr:id>63E0AEE1-6D8D-4425-A06A-F4A943FFAF21</gtr:id><gtr:firstName>David Edgar</gtr:firstName><gtr:surname>Neal</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7FB22B57-F9DC-4560-B487-3019E7738D93"><gtr:id>7FB22B57-F9DC-4560-B487-3019E7738D93</gtr:id><gtr:firstName>Noel</gtr:firstName><gtr:otherNames>W</gtr:otherNames><gtr:surname>Clarke</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0100100"><gtr:id>3351E9FF-EFE6-45AE-BC5B-BFD836490B71</gtr:id><gtr:title>Northern (&amp;amp; Bristol) Prostate Cancer Collaborative - Newcastle component Molecular mechanisms and the development of no</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100100</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-01-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3155161</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E7095B45-C50F-4D45-983E-DE7D6AB63C37</gtr:id><gtr:title>Outcome of transurethral prostatectomy for the palliative management of lower urinary tract symptoms in men with prostate cancer.</gtr:title><gtr:parentPublicationTitle>International journal of urology : official journal of the Japanese Urological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72313d0b4fb74aa7f876af123ebcad82"><gtr:id>72313d0b4fb74aa7f876af123ebcad82</gtr:id><gtr:otherNames>Gnanapragasam VJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0919-8172</gtr:issn><gtr:outcomeId>9EA44B3DB2F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DFC243B-6851-4135-90AB-53A040ACE10B</gtr:id><gtr:title>Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f69551d9c96ceb037d387cf751a53042"><gtr:id>f69551d9c96ceb037d387cf751a53042</gtr:id><gtr:otherNames>Darby S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>7BFA7C89769</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63F1D529-3A76-4F5D-9A30-39EDA35C6C58</gtr:id><gtr:title>The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b27ff50d0bfaf49d2437a6da8c0342d6"><gtr:id>b27ff50d0bfaf49d2437a6da8c0342d6</gtr:id><gtr:otherNames>Clark EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>B339A4E8B39</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74E52E6F-FCD6-4C9A-BD52-5262EFCD8D44</gtr:id><gtr:title>Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ce51e73d5cbb9d457cdf8fb79c995b8"><gtr:id>5ce51e73d5cbb9d457cdf8fb79c995b8</gtr:id><gtr:otherNames>Rodgers M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>C41D653D7A4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43EA1BCD-5F10-46ED-90E2-294631EFEEC4</gtr:id><gtr:title>Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f68a702ef5ec550ca56df961f101e510"><gtr:id>f68a702ef5ec550ca56df961f101e510</gtr:id><gtr:otherNames>Logan IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>D7BBAF8CE2F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66213430-45E9-4010-8802-FCE81E437E04</gtr:id><gtr:title>A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/131290eb61bf5bf74038ca79e8512782"><gtr:id>131290eb61bf5bf74038ca79e8512782</gtr:id><gtr:otherNames>Mills N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>E724569ED86</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82F39F7C-F06A-4AF1-A708-EEC872BE2D75</gtr:id><gtr:title>Role of the AP2 beta-appendage hub in recruiting partners for clathrin-coated vesicle assembly.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b6e9cb21a3710540b05055c789f346a"><gtr:id>3b6e9cb21a3710540b05055c789f346a</gtr:id><gtr:otherNames>Schmid EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>EBB2969E63F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E6FE503-F156-464C-A7A1-E3EF166C809C</gtr:id><gtr:title>SIGN: no. 85--management of transitional cell carcinoma of the bladder.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7508a3fb467e8c729a0bb445408afd01"><gtr:id>7508a3fb467e8c729a0bb445408afd01</gtr:id><gtr:otherNames>Neal DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>F2F617ACD42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2280CE8C-E300-48DA-9625-F0750D0965AF</gtr:id><gtr:title>Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e696d3f5e350b410fd12af7d00cfc3d"><gtr:id>6e696d3f5e350b410fd12af7d00cfc3d</gtr:id><gtr:otherNames>Fong CW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>F76FD988C75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D456848F-2590-4446-90CE-E0F2D18D49F1</gtr:id><gtr:title>Cellular functions of TIP60.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31c6b20d635113b9ee2f330171e4394f"><gtr:id>31c6b20d635113b9ee2f330171e4394f</gtr:id><gtr:otherNames>Sapountzi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn><gtr:outcomeId>545F1226622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC739BFB-1005-4FFC-9046-F53D3CCD22AB</gtr:id><gtr:title>Sprouty and cancer: the first terms report.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d081338774536ff58171c1aac0e1f13f"><gtr:id>d081338774536ff58171c1aac0e1f13f</gtr:id><gtr:otherNames>Lo TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn><gtr:outcomeId>C0892302C79</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2681B168-43BF-4E87-87CB-02AB665D28B3</gtr:id><gtr:title>KGF suppresses alpha2beta1 integrin function and promotes differentiation of the transient amplifying population in human prostatic epithelium.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/957b35b6411b395c9dec34a4ac6b4e71"><gtr:id>957b35b6411b395c9dec34a4ac6b4e71</gtr:id><gtr:otherNames>Heer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>3C7748F6083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24033D0F-5D8C-4E86-A864-6E2EDE29EA7C</gtr:id><gtr:title>NF-kappaB activation upregulates fibroblast growth factor 8 expression in prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/042b3e90146043230abd551b4b579fc3"><gtr:id>042b3e90146043230abd551b4b579fc3</gtr:id><gtr:otherNames>Armstrong K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>503FC3E33EC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57CC8EB5-027D-4F72-8658-73E741852955</gtr:id><gtr:title>The developing role of receptors and adaptors.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01c2c81efb7071071910fd358233b8e5"><gtr:id>01c2c81efb7071071910fd358233b8e5</gtr:id><gtr:otherNames>Massie C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>0BB7D31A68B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B14738B-C5B4-4923-92E5-EFB41A71D13F</gtr:id><gtr:title>Fournier's gangrene.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a07a9b6ce058602c99ab96d2ee3394a9"><gtr:id>a07a9b6ce058602c99ab96d2ee3394a9</gtr:id><gtr:otherNames>'Aho T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1743-4270</gtr:issn><gtr:outcomeId>A559274039C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18EE5680-A51E-4592-876F-9A8AFEA679BC</gtr:id><gtr:title>Establishing a robotic prostatectomy programme: The impact of mentoring using a structured approach.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa749e25f296616d3f5df963825a09a2"><gtr:id>aa749e25f296616d3f5df963825a09a2</gtr:id><gtr:otherNames>Kaul SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>47BAE7E6A84</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100100</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>